These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 15996327

  • 1. [The value of serum tumor marker in the diagnosis of lung cancer].
    Shi GL, Hu XL, Yue SD, Song CX.
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
    [Abstract] [Full Text] [Related]

  • 2. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F, Li WM, Wang DM, Gao SS, Bao Y, Chen WB, Liu D.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N.
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [Abstract] [Full Text] [Related]

  • 4. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM, Sauer-Eppel H, Bruzdziak TH.
    Anticancer Res; 2007 Sep; 27(4A):1911-5. PubMed ID: 17649794
    [Abstract] [Full Text] [Related]

  • 5. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R, Li R, Wang Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [Abstract] [Full Text] [Related]

  • 6. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Jan; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 7. [Tumor markers in lung cancer].
    Niho S, Shinkai T.
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [Abstract] [Full Text] [Related]

  • 8. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 Dec; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 9. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
    Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T.
    Cancer; 2000 Oct 15; 89(8):1677-83. PubMed ID: 11042560
    [Abstract] [Full Text] [Related]

  • 10. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H.
    Anticancer Res; 2004 Oct 15; 24(3b):1941-6. PubMed ID: 15274381
    [Abstract] [Full Text] [Related]

  • 11. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR, Zhang X, Xu ZF, Zheng S.
    Ai Zheng; 2002 Feb 15; 21(2):196-9. PubMed ID: 12479076
    [Abstract] [Full Text] [Related]

  • 12. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K.
    Anticancer Res; 1999 Feb 15; 19(4A):2673-8. PubMed ID: 10470218
    [Abstract] [Full Text] [Related]

  • 13. [Serum tumor markers for lung cancer diagnosis.].
    Liang Z, Xu S, Liu Z, Zhou S, Song X.
    Zhongguo Fei Ai Za Zhi; 2008 Apr 20; 11(2):256-9. PubMed ID: 20731912
    [Abstract] [Full Text] [Related]

  • 14. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P.
    J Exp Clin Cancer Res; 2000 Dec 20; 19(4):477-81. PubMed ID: 11277326
    [Abstract] [Full Text] [Related]

  • 15. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM.
    Anticancer Res; 2005 Dec 20; 25(3A):1773-8. PubMed ID: 16033098
    [Abstract] [Full Text] [Related]

  • 16. [Detection of serum CK19-2G2 and Cyfra21-1 protein and comparison of their diagnostic value for lung cancer].
    Gao J, Wang H, Qi J.
    Zhonghua Zhong Liu Za Zhi; 2008 Dec 20; 30(12):930-2. PubMed ID: 19173996
    [Abstract] [Full Text] [Related]

  • 17. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
    Zhang S, Ma Y, Yang X.
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 May 20; 22(5):271-3. PubMed ID: 11775851
    [Abstract] [Full Text] [Related]

  • 18. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 May 20; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 19. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
    Tan Y, Zhang P, Zheng C.
    Zhonghua Zhong Liu Za Zhi; 1999 Jul 20; 21(4):287-9. PubMed ID: 11776818
    [Abstract] [Full Text] [Related]

  • 20. [Serum tumor markers for primary lung carcinoma].
    Watanabe R, Takiguchi Y, Kuriyama T.
    Nihon Rinsho; 2000 May 20; 58(5):1070-3. PubMed ID: 10824551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.